Even though the medical relevance of the aforementioned cardiovascular chance factor alterations by tirzepatide will probably be assessed in the prepared cardiovascular consequence review SURPASS-CVOT ( "form":"clinical-demo","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Investiga